Needle Ablation Using Radio
Frequency Current as a Treatment
for Benign Prostatic Hyperplasia:
Experimental Results in ex vivo
Human Prostate

Ramon, Jacob; Goldwasser, Benad; Shenfeld, Ofer Z.; Engelberg, S; Rasor, Julia S.; Edwards, S.

doi:10.1159/000474338

Cited by 34 publications

(9 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The electrode's tip length determines the length of the lesion; other variables, e.g. similar to that used in the prostate and includes microwave and impedance heating [7]. lesion current, power, voltage and accumulation rate, also influence lesion size.…”

Section: Treatment Outcome Sexual Function In General the Change In mentioning

confidence: 99%

“…After initial to 71°C, with a mean of 54°C. In an experimental model with the TUNA system using an infrared thermalstudies in animal and ex vivo human models [6,7] its eÂect in men with symptomatic BPH was determined, as imaging device, it was shown that tip temperatures were 20-40°C higher than shield temperatures [16]. Based clinical experience with TUNA was limited.…”

Section: Treatment Outcome Sexual Function In General the Change In mentioning

confidence: 99%

“…Earlier feasibility studies morbidity and mortality associated with such a common surgical procedure has obvious consequences for patients showed that TUNA treatment creates well-defined necrotic lesions within the prostate, while sparing the and the healthcare system, and has led to a search for alternative treatments [4,5]. Current developments and urethra and adjacent organs such as the rectum and bladder [6,7]. Initial clinical studies showed that TUNA anticipated changes in the management of BPH include the establishment of an improved scoring system and treatment in the management of BPH improved symptom scores and peak flow rates, with low morbidity [8], and response criteria, pharmacological therapies, transurethral implants and heat therapies.…”

Section: Introduction Waves Electrocauterization and Radiofrequency mentioning

confidence: 99%

See 2 more Smart Citations

Transurethral needle ablation of the prostate for the treatment of benign prostatic hyperplasia: a collaborative multicentre study

Ramon¹,

Lynch²,

Eardley³

et al. 1997

British Journal of Urology

View full text Add to dashboard Cite

Objective To assess the efficacy and safety of transurethral needle ablation of the prostate (TUNA) for patients with symptomatic benign prostatic hyperplasia (BPH) in a multicentre trial. Patients and methods Seventy‐six patients were recruited from five centres; all were treated with the TUNA system consisting of a powered radiofrequency generator and a TUNA catheter. The patients were evaluated prospectively using the international prostate symptom score (IPSS), uroflowmetry, quality‐of‐life score, and other variables, and followed for a mean of 12 months after treatment. Results Sixty‐eight patients were available for follow‐up; TUNA produced significant improvements in the IPSS (median 22 before, to 7.5 after treatment), urinary flow rate (mean 8.7 before, to 11.6 mL/s after treatment) and quality‐of‐life score (median 5 before, to 2 after treatment) at 12 months. Conclusions If these early promising results are maintained in the medium to long term, TUNA therapy will be a useful low‐morbidity alternative for patients with symptomatic BPH.

show abstract

Section: Treatment Outcome Sexual Function In General the Change In mentioning

confidence: 99%

Section: Treatment Outcome Sexual Function In General the Change In mentioning

confidence: 99%

Section: Introduction Waves Electrocauterization and Radiofrequency mentioning

confidence: 99%

See 1 more Smart Citation

Transurethral needle ablation of the prostate for the treatment of benign prostatic hyperplasia: a collaborative multicentre study

Ramon¹,

Lynch²,

Eardley³

et al. 1997

British Journal of Urology

View full text Add to dashboard Cite

show abstract

“…Such a device has been shown to or at any time during the 12-month follow-up were included in the analysis. produce extremely localized thermal lesions in animal [2] and human tissues, both ex vivo [3] and in vivo [4].…”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of transurethral needle ablation of the prostate for symptomatic outlet obstruction

Rosario

Woo

Potts

et al. 1997

British Journal of Urology

View full text Add to dashboard Cite

Objectives To examine, in an observational study, the safety and efficacy of transurethral needle ablation (TUNA) of the prostate as a treatment for symptomatic benign prostatic enlargement. Patients and methods This prospective study included 71 symptomatic men with unequivocal obstruction on pressure‐flow urodynamics. The variables measured at baseline and up to 12 months after treatment included the American Urological Association (AUA)‐7 symptom index and an added quality‐of‐life question, the AUA BPH‐Impact Index, a sexual function score, transrectal ultrasonography of the prostate, a frequency‐volume chart, free‐flow uroflowmetry, post‐void residual urine volume (PVR) and pressure‐flow urodynamics. Transurethral resection of the prostate (TURP) was offered if the symptoms failed to resolve at any time during the follow‐up period. TUNA was performed under local anaesthetic and sedation in 63 (89%) men and as a day‐case procedure in 10 (14%). Five patients were on warfarin which was not discontinued. Results There were no serious treatment‐related adverse events. Eight of the initial nine patients who were not routinely catheterized after treatment with TUNA developed acute urinary retention. Although some haematuria occurred in all patients, only one (1.4%) developed catheter blockage by clot. There were no problems with bleeding in those patients on warfarin at the time of treatment. The mean (95% confidence interval, CI) AUA‐7 index fell from 23 (1.7) to 10.6 (1.8) (P<0.001, Mann–Whitney U‐test) at 12 months, 29 men (41%) had an AUA‐7 index of ≤7. The maximum (95% CI) urinary flow rate increased from 9.0 (0.8) to 11.3 (1.1) mL/s (P<0.001) and this was accompanied by a small but significant reduction in PVR of 70 (14) mL to 35 (8) mL (P<0.001 Mann–Whitney U‐test). There was a significant reduction in both maximal voiding pressure and detrusor pressure at peak flow at 3 months (Mann–Whitney U‐test, both P<0.001) and at 12 months (P<0.001, Wilcoxon matched‐pairs signed‐ranks test). However, 78% of the 45 men undergoing repeat pressure‐flow studies at 12 months were unequivocally obstructed according to the Abrams‐Griffiths nomogram. The mean (95% CI) prostatic volume fell from 49.0 (4.8) mL at baseline to 40.8 (4.9) mL at 3 months, but this change was not statistically significant (P=0.011, Mann–Whitney U‐test). Two men reported erectile dysfunction, one experienced ejaculatory problems and seven reported an improvement in erectile function after TUNA. During the study, 22 men (31%) underwent TURP. Conclusions TUNA is a safe treatment which can be performed as an out‐patient procedure under local anaesthesia and sedation in the vast majority of patients. There was no evidence of serious adverse events and no significant adverse effect on sexual function. The symptomatic improvement was sustained at 12 months in most (54%) patients, with modest improvements in peak flow rate, PVR and voiding pressures, indicating that TUNA may result in prolonged symptomatic improvement in a proportion of patients sufferin...

show abstract

“…The transurethral needle ablation (TUNA) device has recently been developed to treat BPH by selectively ablating hyperplastic prostatic tissue [1][2][3]. A special catheter incorporates needles that deliver low level radiofrequency (RF) power directly to a very localized area of 1 ran…”

Section: Introductionmentioning

confidence: 99%

Transurethral Needle Ablation (TUNA): Thermal Gradient Mapping and Comparison of Lesion Size in a Tissue Model and in Patients with Benign Prostatic Hyperplasia

Js¹,

Ar²,

Sd³

et al. 1993

Eur Urol

Self Cite

View full text Add to dashboard Cite

Needle Ablation Using Radio Frequency Current as a Treatment for Benign Prostatic Hyperplasia: Experimental Results in ex vivo Human Prostate

Cited by 34 publications

References 7 publications

Transurethral needle ablation of the prostate for the treatment of benign prostatic hyperplasia: a collaborative multicentre study

Transurethral needle ablation of the prostate for the treatment of benign prostatic hyperplasia: a collaborative multicentre study

Safety and efficacy of transurethral needle ablation of the prostate for symptomatic outlet obstruction

Transurethral Needle Ablation (TUNA): Thermal Gradient Mapping and Comparison of Lesion Size in a Tissue Model and in Patients with Benign Prostatic Hyperplasia

Contact Info

Product

Resources

About